65847-85-0 | 2-(morpholin-4-yl)ethyl 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylate

Packsize	Purity	Availability	Price	Discounted Price
5mg	96%	in stock	$74.00	$52.00
10mg	96%	in stock	$133.00	$93.00
25mg	96%	in stock	$262.00	$183.00
100mg	96%	in stock	$603.00	$422.00
250mg	96%	in stock	$945.00	$661.00
1g	96%	in stock	$2,344.00	$1,641.00

Description

• Catalog Number: AD11050
• Chemical Name: 2-(morpholin-4-yl)ethyl 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylate
• CAS Number: 65847-85-0
• Molecular Formula: C19H20F3N3O3
• Molecular Weight: 395.3756
• MDL Number: MFCD00866144
• SMILES: O=C(c1cccnc1Nc1cccc(c1)C(F)(F)F)OCCN1CCOCC1

Computed Properties

• Complexity: 501
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 7
• XLogP3: 3.7

Literature

• Italian guidelines for primary headaches: 2012 revised version.

  The journal of headache and pain 20120501

• Laboratory monitoring of patients treated with antihypertensive drugs and newly exposed to non steroidal anti-inflammatory drugs: a cohort study.

  PloS one 20120101

• Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.

  Healthcare informatics research 20101201

• Effects of perioperative intravenous low dose of ketamine on postoperative analgesia in children.

  European journal of anaesthesiology 20100101

• Drug use in children: cohort study in three European countries.

  BMJ (Clinical research ed.) 20080101

• Acute regulation of the SLC26A3 congenital chloride diarrhoea anion exchanger (DRA) expressed in Xenopus oocytes.

  The Journal of physiology 20030515

• Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients.

  Rheumatology (Oxford, England) 20011101

• Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.

  Immunopharmacology and immunotoxicology 20011101

• Modulation of arachidonic acid metabolism by orally administered morniflumate in man.

  Agents and actions 19910701

• [A new anti-inflammatory-analgesic-antipyretic, morniflumate, in the treatment of chronic recurring bronchitis].

  Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences medicales et pharmacologiques 19910101

• A gastroprotective anti-inflammatory agent: the beta-morpholinoethyl ester of niflumic acid (morniflumate).

  Agents and actions 19840201